BRIEF-Rapport Therapeutics Presents Rap-219 Focal Onset Seizure Phase 2A Follow-Up Period Results

Rapport Therapeutics

Rapport Therapeutics

RAPP

0.00

- Rapport Therapeutics Inc RAPP.O:

  • RAPPORT THERAPEUTICS PRESENTS RAP-219 FOCAL ONSET SEIZURE PHASE 2A FOLLOW-UP PERIOD RESULTS DEMONSTRATING SUSTAINED SEIZURE REDUCTION AT THE 2026 AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING

  • RAPPORT THERAPEUTICS INC: RAP-219 WAS GENERALLY WELL TOLERATED THROUGHOUT TREATMENT AND FOLLOW-UP PERIODS

Source text: ID:nGNXc7bNXC

Further company coverage: RAPP.O